Business

Know the Business

Centene is the largest Medicaid managed care company in America — a $195 billion government-funded health insurance middleman that earns about 2 cents on every premium dollar in a good year and loses money in a bad one. The stock trades near book value after a brutal 2025 ($6.7 billion goodwill impairment, Medicaid cost pressures, ACA subsidy expiration), and the market is debating whether management can close a 200+ basis point gap between medical cost trends and state rate increases. The single variable that matters most: Medicaid HBR, which peaked at 94.9% in Q2 2025 and improved to 93.0% by Q4 — whether that trajectory continues into 2026 will determine if this is a turnaround or a value trap.

How This Business Actually Works

Centene collects fixed monthly premiums from governments, pays variable medical costs to providers, and keeps the spread — a model where the difference between a great year and a terrible one is 3 percentage points of margin.

States and the federal government pay Centene a per-member-per-month (PMPM) capitation rate to manage healthcare for Medicaid, Medicare, and ACA Marketplace enrollees. Centene's job is to build provider networks, manage utilization, and spend less on medical care than it collects. The economics are brutally simple:

The critical insight: a 100 basis point HBR change on $175 billion in premium revenue equals a $1.75 billion swing in profit. That single ratio explains the entire difference between FY2023 ($2.7B net income) and FY2025 (adjusted net income near $1B).

Two structural features distinguish Centene from peers. First, it deliberately does not own a PBM — unlike UnitedHealth (Optum Rx), CVS/Aetna, or Cigna (Evernorth). Management argues this lets them shop PBMs competitively against a $60 billion pharmacy spend. Second, scale primarily helps on SG&A (improved from 8.5% to 7.4% in one year) but barely moves the medical cost needle, because provider networks and utilization patterns are fundamentally local.

Revenue grew 4x from 2016 to 2024 — mostly through acquisitions (the 2020 jump is WellCare). But operating margins have oscillated between 0.9% and 3.1% with no upward trend. Scale has not translated into margin expansion. This is the central challenge of the Centene thesis.

The Playing Field

Centene is the fourth-largest US health insurer by revenue but trades at a fraction of its peers' market caps — a valuation discount that reflects structural margin inferiority, not a temporary glitch.

FY2024 financials used for margins (FY2025 distorted by impairments for CNC, HUM). Current market data for valuation. CI and UNH revenue includes large pharmacy/services businesses inflating the top line.

The most damning comparison is Molina (MOH). Molina runs essentially the same Medicaid-focused managed care business at one-quarter the scale — and generates 4.2% operating margins versus Centene's 1.9%. If scale were the advantage CNC claims, Molina should have worse margins, not better ones. Molina's edge: simpler operations, no large M&A integration overhead, and arguably better state-level execution.

UnitedHealth operates in a different league. Its 8% operating margins reflect Optum's high-margin healthcare services business, not superior insurance operations. Elevance (the former Anthem) is the more relevant benchmark for what "good" looks like in Medicaid managed care — 5% operating margins with a similar government-focused book.

The bull case for CNC requires believing that the SG&A improvements (8.5% to 7.4%) and Medicaid rate catches will eventually close the gap to Elevance-like margins. Historically, that gap has persisted.

Is This Business Cyclical?

Centene faces three overlapping cycles — medical cost, enrollment, and policy — and 2024-2025 was the rare moment when all three turned negative simultaneously.

FY2025 excluded (operating margin -3.9% distorted by $6.7B goodwill impairment). Adjusted operating margin was likely near 1-2%.

Medical cost cycle. This is what actually drives earnings. Post-COVID utilization normalization hit the entire MCO sector in 2021-2022. For Centene specifically, behavioral health — particularly Applied Behavior Analysis (ABA) therapy — drove roughly half of excess Medicaid cost trend in 2025. Management found outlier ABA providers billing 40 hours/week for 5-10 years per child (optimal is 2-3 years of balanced care). An internal task force achieved 45% reductions in outlier payment rates in one state. This is the kind of cost that states eventually address through rate adjustments and program reforms, but the lag hurts.

Enrollment cycle. Medicaid enrollment is counter-cyclical — it rises during recessions as more people qualify. But the 2023-2024 redetermination unwind (post-COVID continuous enrollment ended) shed over 2 million members. The members who left were disproportionately healthier, raising the acuity and cost of the remaining pool. This is now stabilizing: management expects 5-6% member-month attrition in 2026 from eligibility tightening and specific contract changes (Florida rolloff, New York essential plan).

Policy cycle. The Enhanced Advance Premium Tax Credits (EAPTCs) that turbocharged ACA Marketplace enrollment expired in 2025. Centene's Marketplace membership will fall from 5 million (peak) to roughly 3.5 million. Management repriced aggressively — mid-30% average rate increases for 2026 — and shifted the mix toward Bronze products (over 30% of enrollment, up from 19-24% historically). Bronze members are generally healthier and more price-sensitive, which should be margin-positive, but this is unproven at scale.

The Metrics That Actually Matter

If you understand five numbers, you understand Centene. Everything else is noise.

Medicaid HBR is the single most important number. Centene's Medicaid book is roughly $124 billion in annual premium revenue. At a 93.7% HBR, the segment is barely profitable after SG&A. Every 100 bps of HBR improvement releases approximately $1.2 billion. Getting to 91-92% — where it was in early 2024 — would add $2-3 billion in annual pre-tax earnings.

The rate-vs-trend gap is the leading indicator. In FY2025, Centene received a composite 5.5% rate increase but experienced "mid-six" medical cost trend — meaning rates were still underwater. For 2026, management expects "mid-fours" net trend, implying the gap is closing. When rate increases consistently exceed trend, margin expansion follows with a 12-18 month lag.

The market fixates on EPS guidance, but the HBR and rate gap tell you where EPS is going before management does.

What I'd Tell a Young Analyst

Watch quarterly Medicaid HBR, not annual. The Q2-to-Q4 2025 trajectory (94.9% to 93.0%) tells you more than any annual figure or EPS beat/miss. If Q1-Q2 2026 prints below 93%, the turnaround is real.

The market may be overestimating how structural CNC's margin problem is. Behavioral health costs — especially ABA therapy — are being actively reformed by states. Rate catch-ups are coming with two years of post-redetermination acuity data now in the actuarial base. Management guided conservatively ("I will be disappointed if 93.7% is all we can deliver" — CEO Sarah London, Q3 2025 call).

The market may be underestimating Marketplace risk. A 30%+ membership decline with a shift to an unproven Bronze-heavy mix is a real experiment. One bad flu season or adverse selection spiral in a lower-subsidy environment could wipe out the 4% pretax margin target.

The Magellan divestiture and $6.7 billion goodwill write-down signal management is cleaning house after an acquisition-heavy era. The question is whether this is disciplined capital allocation or a confession that the empire-building model never created value. Goodwill fell from $17.6 billion to $10.8 billion — a tacit admission that roughly 40% of acquisition value was illusory.

If you want to own managed care, the hard question is: why Centene over Molina? Molina does the same Medicaid business at higher margins with less complexity and no acquisition hangover. CNC's bull case requires believing that scale advantages will eventually materialize in margins. Nine years of data say they haven't. But the stock at book value may already reflect that pessimism — and if HBR reverts to 91-92%, adjusted EPS could significantly exceed the conservative above-$3 guidance.